The Downregulation of eIF3a Contributes to Vemurafenib Resistance in Melanoma by Activating ERK via PPP2R1B

MLA

Shi-Long Jiang, et al. “The Downregulation of EIF3a Contributes to Vemurafenib Resistance in Melanoma by Activating ERK via PPP2R1B.” Frontiers in Pharmacology, vol. 12, Aug. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....df54d58c9172c08b0e97e3a770470eb6&authtype=sso&custid=ns315887.

APA

Shi-Long Jiang, Zhi-Bin Wang, Tao Zhu, Ting Jiang, Jiang-Feng Fei, Chong Liu, Chao Luo, Yan Cheng, & Zhao-Qian Liu. (2021). The Downregulation of eIF3a Contributes to Vemurafenib Resistance in Melanoma by Activating ERK via PPP2R1B. Frontiers in Pharmacology, 12.

Chicago

Shi-Long Jiang, Zhi-Bin Wang, Tao Zhu, Ting Jiang, Jiang-Feng Fei, Chong Liu, Chao Luo, Yan Cheng, and Zhao-Qian Liu. 2021. “The Downregulation of EIF3a Contributes to Vemurafenib Resistance in Melanoma by Activating ERK via PPP2R1B.” Frontiers in Pharmacology 12 (August). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....df54d58c9172c08b0e97e3a770470eb6&authtype=sso&custid=ns315887.